---
title: "Kisspeptin-10"
canonical_url: https://peptidelibrary.app/library/kisspeptin-10
description: "Decapeptide KISS1 fragment that stimulates GnRH release. Used in reproductive-endocrine research. WADA lists kisspeptin and agonists as S2. Not FDA-approved."
updated: 2026-09-26
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Kisspeptin-10

Kisspeptin-10 (also called Kp-10 or Metastin 45-54) is a kisspeptin fragment in the GnRH Modulator class. Kisspeptin-10 is the C-terminal decapeptide fragment of the KISS1 gene product and retains full activity at KISS1R, the G protein-coupled receptor formerly called GPR54.

Decapeptide KISS1 fragment that stimulates GnRH release. Used in reproductive-endocrine research. WADA lists kisspeptin and agonists as S2. Not FDA-approved.

Also known as: Kp-10, Metastin 45-54, Kisspeptin-112-121.

Categories: Experimental.

## Classification

- Type: Kisspeptin fragment / research
- Mechanism class: GnRH Modulator
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Kisspeptin-10 is the C-terminal decapeptide fragment of the KISS1 gene product and retains full activity at KISS1R, the G protein-coupled receptor formerly called GPR54. Kisspeptin neurons in the arcuate nucleus and preoptic area sit immediately upstream of GnRH neurons and are the principal gatekeeper of GnRH pulsatility, integrating sex steroid feedback, nutritional status and circadian input. Receptor activation on GnRH neurons depolarises them and triggers GnRH release, raising luteinising and follicle-stimulating hormone. Because the fragment is cleared within minutes, sustained stimulation in research settings requires infusion or repeated dosing.

Targets: KISS1R (GPR54).

Origin: Synthetic C-terminal kisspeptin fragment.

## Properties

- Sequence: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂
- Length: 10
- Molecular formula: C63H83N17O14
- Molecular weight: 1,302.5 g/mol
- CAS number: 374675-21-5
- Half-life: ~4 minutes
- Studied routes: Intravenous

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Early or uncontrolled human studies
- Human trials: 1
- Controlled human trials: 0
- Preclinical sources: 0
- Latest source: 2025

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. EBioMedicine. 2025. 2025. Human study (early or uncontrolled). Population: Healthy adults across several study groups. Luteinising hormone response. Research on a related compound, not this one. Limitations: Studied an analog, not Kisspeptin-10 itself [Source](https://pubmed.ncbi.nlm.nih.gov/40215751/)
2. Sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans. Eur J Endocrinol. 2025. 2025. Human study (early or uncontrolled). Population: Healthy adults (n=12, 50% female). Oxytocin response, by sex [Source](https://pubmed.ncbi.nlm.nih.gov/39965102/)
3. Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men. J Clin Endocrinol Metab. 2022. 2022. Human study (early or uncontrolled). Population: Healthy men. Bone formation and resorption markers. Research on a related compound, not this one. Limitations: Studied an analog, not Kisspeptin-10 itself [Source](https://pubmed.ncbi.nlm.nih.gov/35244717/)
4. NCT03771326 — KP-10 and Insulin Secretion in Men. Human study (early or uncontrolled). Population: Men (n=14). Insulin secretion. Limitations: Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT03771326)

### Registered trials

- [NCT03771326](https://clinicaltrials.gov/study/NCT03771326)

## Safety

Side effects: Flushing; LH surge effects.

Risks: WADA S2.

Contraindications: Hormone-sensitive cancers.

Human safety basis: Limited human reports

Key limitations: No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Kisspeptin-10 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is Kisspeptin-10?

Decapeptide KISS1 fragment that stimulates GnRH release. Used in reproductive-endocrine research. WADA lists kisspeptin and agonists as S2. Not FDA-approved.

### How does Kisspeptin-10 work?

Kisspeptin-10 is the C-terminal decapeptide fragment of the KISS1 gene product and retains full activity at KISS1R, the G protein-coupled receptor formerly called GPR54. Kisspeptin neurons in the arcuate nucleus and preoptic area sit immediately upstream of GnRH neurons and are the principal gatekeeper of GnRH pulsatility, integrating sex steroid feedback, nutritional status and circadian input.

### Is Kisspeptin-10 FDA approved?

No. Kisspeptin-10 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. FDA's compounding lists show 503A Category 2: FDA identified significant safety risks.

### What is the half-life of Kisspeptin-10?

Reported half-life for Kisspeptin-10 is ~4 minutes. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of Kisspeptin-10?

Kisspeptin-10 has the sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂, giving a chain of 11 amino acids. Its molecular formula is C63H83N17O14.

### Is Kisspeptin-10 banned in sport?

Kisspeptin-10 is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [Safety Evaluation of KP-10 (Metastin 45-54) Following once Daily Intravenous Administration for 14 Days in Dog — Int J Toxicol, 2021](https://pubmed.ncbi.nlm.nih.gov/34126799/)
- [The kisspeptin analog C6 elicits greater tachyphylaxis and transcriptional activation than kisspeptin-10 and -54 — Mol Cell Endocrinol, 2026](https://pubmed.ncbi.nlm.nih.gov/42379494/)
- [Synthesis and characterisation of DOTA-kisspeptin-10 as a potential gallium-68/lutetium-177 pan-tumour radiopharmaceutical — J Neuroendocrinol, 2025](https://pubmed.ncbi.nlm.nih.gov/39775975/)
- [Investigating the detection of the novel doping‐relevant peptide kisspeptin‐10 in urine using liquid chromatography high‐resolution mass spectrometry — Biomed Chromatogr, 2024](https://pubmed.ncbi.nlm.nih.gov/38978171/)
- [Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src — Nat Commun, 2024](https://pubmed.ncbi.nlm.nih.gov/38346942/)
